SE514982C2 - Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning - Google Patents

Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning

Info

Publication number: SE514982C2
Authority: SE; Sweden
Prior art keywords: carrier; hpv; protein; human papillomavirus; polynucleotide
Prior art date: 1999-09-30

Application number

SE9903534A

Other languages

English (en)

Swedish (sv)

Other versions

SE9903534D0 (sv

SE9903534L (sv

Inventor

Per Antonsson

Karin Kristensson

Marie Wallen-Oehman

Joakim Dillner

Peter Lando

Original Assignee

Active Biotech Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-09-30

Filing date

1999-09-30

Publication date

2001-05-28

1999-09-30 Application filed by Active Biotech Ab filed Critical Active Biotech Ab

1999-09-30 Priority to SE9903534A priority Critical patent/SE514982C2/sv

1999-09-30 Publication of SE9903534D0 publication Critical patent/SE9903534D0/xx

2000-09-19 Priority to IL14874100A priority patent/IL148741A0/xx

2000-09-19 Priority to PL00355012A priority patent/PL355012A1/pl

2000-09-19 Priority to CA002384723A priority patent/CA2384723A1/en

2000-09-19 Priority to AU76951/00A priority patent/AU771481B2/en

2000-09-19 Priority to BR0014666-8A priority patent/BR0014666A/pt

2000-09-19 Priority to TR2002/00802T priority patent/TR200200802T2/xx

2000-09-19 Priority to DE60025016T priority patent/DE60025016D1/de

2000-09-19 Priority to SK422-2002A priority patent/SK4222002A3/sk

2000-09-19 Priority to PCT/SE2000/001808 priority patent/WO2001023422A1/en

2000-09-19 Priority to NZ516725A priority patent/NZ516725A/xx

2000-09-19 Priority to YU22202A priority patent/YU22202A/sh

2000-09-19 Priority to HR20020092A priority patent/HRP20020092A2/hr

2000-09-19 Priority to AT00966633T priority patent/ATE313559T1/de

2000-09-19 Priority to HU0202770A priority patent/HUP0202770A3/hu

2000-09-19 Priority to KR1020027004124A priority patent/KR20020047195A/ko

2000-09-19 Priority to CN00812618A priority patent/CN1373771A/zh

2000-09-19 Priority to EEP200200157A priority patent/EE200200157A/xx

2000-09-19 Priority to JP2001526572A priority patent/JP2003510064A/ja

2000-09-19 Priority to EP00966633A priority patent/EP1222200B1/en

2000-09-19 Priority to CZ20021023A priority patent/CZ20021023A3/cs

2000-09-19 Priority to RU2002111554/13A priority patent/RU2002111554A/ru

2000-09-19 Priority to MXPA02003328A priority patent/MXPA02003328A/es

2001-03-31 Publication of SE9903534L publication Critical patent/SE9903534L/xx

2001-05-28 Publication of SE514982C2 publication Critical patent/SE514982C2/sv

2002-01-31 Priority to ZA200200886A priority patent/ZA200200886B/en

2002-02-08 Priority to NO20020615A priority patent/NO20020615L/no

2004-01-20 Priority to US10/759,125 priority patent/US20040146531A1/en

2004-05-10 Priority to AU2004201964A priority patent/AU2004201964A1/en

Links

241000701806 Human papillomavirus Species 0.000 title claims abstract description 13
101710135729 Major capsid protein L1 Proteins 0.000 title claims abstract description 5
108090000623 proteins and genes Proteins 0.000 claims abstract description 25
102000004169 proteins and genes Human genes 0.000 claims abstract description 24
108091033319 polynucleotide Proteins 0.000 claims abstract description 16
102000040430 polynucleotide Human genes 0.000 claims abstract description 16
239000002157 polynucleotide Substances 0.000 claims abstract description 16
206010028980 Neoplasm Diseases 0.000 claims abstract description 14
108091034117 Oligonucleotide Proteins 0.000 claims abstract description 14
230000003472 neutralizing effect Effects 0.000 claims abstract description 11
229960005486 vaccine Drugs 0.000 claims abstract description 11
239000000126 substance Substances 0.000 claims abstract description 5
108090000765 processed proteins & peptides Proteins 0.000 claims description 17
230000003612 virological effect Effects 0.000 claims description 11
239000000427 antigen Substances 0.000 claims description 10
102000036639 antigens Human genes 0.000 claims description 10
108091007433 antigens Proteins 0.000 claims description 10
230000001580 bacterial effect Effects 0.000 claims description 8
210000001744 T-lymphocyte Anatomy 0.000 claims description 7
230000005875 antibody response Effects 0.000 claims description 7
102000004196 processed proteins & peptides Human genes 0.000 claims description 7
210000004027 cell Anatomy 0.000 claims description 6
230000003071 parasitic effect Effects 0.000 claims description 6
230000001681 protective effect Effects 0.000 claims description 5
241000341655 Human papillomavirus type 16 Species 0.000 claims description 4
230000004927 fusion Effects 0.000 claims description 4
230000004044 response Effects 0.000 claims description 4
239000004480 active ingredient Substances 0.000 claims description 3
230000000599 auto-anti-genic effect Effects 0.000 claims description 2
230000003308 immunostimulating effect Effects 0.000 claims description 2
101710163801 Minor capsid protein L2 Proteins 0.000 claims 1
230000006698 induction Effects 0.000 claims 1
208000015181 infectious disease Diseases 0.000 abstract description 6
238000004519 manufacturing process Methods 0.000 abstract description 6
238000002255 vaccination Methods 0.000 abstract description 6
238000000034 method Methods 0.000 abstract description 5
238000011161 development Methods 0.000 abstract description 4
208000022361 Human papillomavirus infectious disease Diseases 0.000 description 28
230000008696 hypoxemic pulmonary vasoconstriction Effects 0.000 description 16
239000002245 particle Substances 0.000 description 6
230000002265 prevention Effects 0.000 description 6
238000011282 treatment Methods 0.000 description 6
108090000565 Capsid Proteins Proteins 0.000 description 5
102100023321 Ceruloplasmin Human genes 0.000 description 5
241001631646 Papillomaviridae Species 0.000 description 5
201000011510 cancer Diseases 0.000 description 4
210000000234 capsid Anatomy 0.000 description 4
108020001507 fusion proteins Proteins 0.000 description 4
102000037865 fusion proteins Human genes 0.000 description 4
206010008342 Cervix carcinoma Diseases 0.000 description 3
208000009608 Papillomavirus Infections Diseases 0.000 description 3
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
239000000969 carrier Substances 0.000 description 3
201000010881 cervical cancer Diseases 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
231100000590 oncogenic Toxicity 0.000 description 3
230000002246 oncogenic effect Effects 0.000 description 3
208000035143 Bacterial infection Diseases 0.000 description 2
102000043129 MHC class I family Human genes 0.000 description 2
108091054437 MHC class I family Proteins 0.000 description 2
208000030852 Parasitic disease Diseases 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
241000700605 Viruses Species 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
208000021145 human papilloma virus infection Diseases 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
206010059313 Anogenital warts Diseases 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
101710091045 Envelope protein Proteins 0.000 description 1
101710121996 Hexon protein p72 Proteins 0.000 description 1
241000725303 Human immunodeficiency virus Species 0.000 description 1
206010023849 Laryngeal papilloma Diseases 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
101710125418 Major capsid protein Proteins 0.000 description 1
102000007557 Melanoma-Specific Antigens Human genes 0.000 description 1
108010071463 Melanoma-Specific Antigens Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
101710188315 Protein X Proteins 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
102100021696 Syncytin-1 Human genes 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
210000000436 anus Anatomy 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
210000004392 genitalia Anatomy 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
208000009000 laryngeal papillomatosis Diseases 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000012737 microarray-based gene expression Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
238000012243 multiplex automated genomic engineering Methods 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
210000003300 oropharynx Anatomy 0.000 description 1
229960002566 papillomavirus vaccine Drugs 0.000 description 1
230000037361 pathway Effects 0.000 description 1
210000003899 penis Anatomy 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000003908 quality control method Methods 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
208000001307 recurrent respiratory papillomatosis Diseases 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
201000000849 skin cancer Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
229940125575 vaccine candidate Drugs 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
210000003905 vulva Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Oncology (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Biotechnology (AREA)
Communicable Diseases (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Tropical Medicine & Parasitology (AREA)
Mycology (AREA)
Immunology (AREA)
Otolaryngology (AREA)
Plant Pathology (AREA)
Gynecology & Obstetrics (AREA)

SE9903534A 1999-01-15 1999-09-30 Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning SE514982C2 (sv)

Priority Applications (27)

Application Number	Priority Date	Filing Date	Title
SE9903534A SE514982C2 (sv)	1999-09-30	1999-09-30	Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
MXPA02003328A MXPA02003328A (es)	1999-09-30	2000-09-19	Vacuna.
HR20020092A HRP20020092A2 (en)	1999-09-30	2000-09-19	Vaccine
HU0202770A HUP0202770A3 (en)	1999-09-30	2000-09-19	Human papilloma virus vaccine
CA002384723A CA2384723A1 (en)	1999-09-30	2000-09-19	Vaccine
AU76951/00A AU771481B2 (en)	1999-09-30	2000-09-19	Vaccine
BR0014666-8A BR0014666A (pt)	1999-09-30	2000-09-19	Vacina
TR2002/00802T TR200200802T2 (tr)	1999-09-30	2000-09-19	Aşı
DE60025016T DE60025016D1 (de)	1999-09-30	2000-09-19	Fusionsprotein aus HPV-L1 und einem Peptid, das ein VLP bilden kann und als Vehikel zum EInschleusen eines Peptids in eine Zelle dienen kann, sowie dessen medizinische Verwendungen
SK422-2002A SK4222002A3 (en)	1999-09-30	2000-09-19	Vaccine
PCT/SE2000/001808 WO2001023422A1 (en)	1999-09-30	2000-09-19	Vaccine
NZ516725A NZ516725A (en)	1999-09-30	2000-09-19	Use of modified HPV as a carrier for vaccine against cancer or viral infection of human papillomavirus
YU22202A YU22202A (sh)	1999-09-30	2000-09-19	Vakcina
IL14874100A IL148741A0 (en)	1999-09-30	2000-09-19	Vaccine
AT00966633T ATE313559T1 (de)	1999-09-30	2000-09-19	Fusionsprotein aus hpv-l1 und einem peptid, das ein vlp bilden kann und als vehikel zum einschleusen eines peptids in eine zelle dienen kann, sowie dessen medizinische verwendungen
PL00355012A PL355012A1 (pl)	1999-09-30	2000-09-19	Szczepionka
KR1020027004124A KR20020047195A (ko)	1999-09-30	2000-09-19	백신
CN00812618A CN1373771A (zh)	1999-09-30	2000-09-19	疫苗
EEP200200157A EE200200157A (et)	1999-09-30	2000-09-19	Vaktsiin
JP2001526572A JP2003510064A (ja)	1999-09-30	2000-09-19	ワクチン
EP00966633A EP1222200B1 (en)	1999-09-30	2000-09-19	Fusion protein between HPV-L1 and a peptide, capable of forming a VLP and that functions as a vehicle for introduction of a peptide in a cell and medical uses thereof
CZ20021023A CZ20021023A3 (cs)	1999-09-30	2000-09-19	Vakcína
RU2002111554/13A RU2002111554A (ru)	1999-09-30	2000-09-19	Вакцина
ZA200200886A ZA200200886B (en)	1999-09-30	2002-01-31	Vaccine.
NO20020615A NO20020615L (no)	1999-09-30	2002-02-08	Vaksine
US10/759,125 US20040146531A1 (en)	1999-09-30	2004-01-20	Virus-like particles devoid of HPV 16 type-specific antibody epitopes as carriers of peptides for introduction into cells
AU2004201964A AU2004201964A1 (en)	1999-01-15	2004-05-10	Bandwidth transfer switching system

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9903534A SE514982C2 (sv)	1999-09-30	1999-09-30	Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning

Publications (3)

Publication Number	Publication Date
SE9903534D0 SE9903534D0 (sv)	1999-09-30
SE9903534L SE9903534L (sv)	2001-03-31
SE514982C2 true SE514982C2 (sv)	2001-05-28

Family

ID=20417209

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE9903534A SE514982C2 (sv)	1999-01-15	1999-09-30	Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning

Country Status (25)

Country	Link
EP (1)	EP1222200B1 (pl)
JP (1)	JP2003510064A (pl)
KR (1)	KR20020047195A (pl)
CN (1)	CN1373771A (pl)
AT (1)	ATE313559T1 (pl)
AU (1)	AU771481B2 (pl)
BR (1)	BR0014666A (pl)
CA (1)	CA2384723A1 (pl)
CZ (1)	CZ20021023A3 (pl)
DE (1)	DE60025016D1 (pl)
EE (1)	EE200200157A (pl)
HR (1)	HRP20020092A2 (pl)
HU (1)	HUP0202770A3 (pl)
IL (1)	IL148741A0 (pl)
MX (1)	MXPA02003328A (pl)
NO (1)	NO20020615L (pl)
NZ (1)	NZ516725A (pl)
PL (1)	PL355012A1 (pl)
RU (1)	RU2002111554A (pl)
SE (1)	SE514982C2 (pl)
SK (1)	SK4222002A3 (pl)
TR (1)	TR200200802T2 (pl)
WO (1)	WO2001023422A1 (pl)
YU (1)	YU22202A (pl)
ZA (1)	ZA200200886B (pl)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MY139500A (en) *	2003-11-12	2009-10-30	Merck Sharp & Dohme	Optimized expression of hpv 58 l1 in yeast
BRPI0509079B8 (pt) *	2004-03-24	2021-07-06	Merck & Co Inc	molécula de ácido nucléico, vetor, célula hospedeira, partículas tipo vírus, método para produzir vlps, vacina, composições farmacêuticas, e, métodos para evitar infecção por hpv e para induzir uma resposta imune em um animal
DE102004036913A1 (de) *	2004-07-16	2006-02-09	Responsif Gmbh	Verwendung von Pentameren zur Herstellung eines Medikaments
CN1796403B (zh) *	2004-12-22	2010-04-28	三峡大学	用于多型人乳头瘤病毒感染防治的多肽和疫苗
CN100392084C (zh) *	2006-03-13	2008-06-04	曾毅	含密码子优化型hpv16l1基因的重组腺病毒
CN101914139B (zh) *	2010-07-16	2012-11-21	四川大学	人类乳头瘤病毒(hpv)衣壳蛋白l1多肽及其制备与应用
MY202196A (en)	2017-06-23	2024-04-16	Verimmune Inc	Chimeric virus-like particles and uses thereof as antigen-specific redirectors of immune responses
WO2020139978A1 (en)	2018-12-27	2020-07-02	Verimmune Llc	Conjugated virus-like particles and uses thereof as anti-tumor immune redirectors
EP3920967A4 (en) *	2019-02-08	2023-01-18	Rensselaer Polytechnic Institute	CONTRACEPTIVE VACCINE BASED ON SPER-ASSOCIATED PROTEIN CATSPER
AU2021364548A1 (en)	2020-10-19	2023-06-08	Verimmune Inc.	Virus-inspired compositions and methods of redirecting preexisting immune responses using the same for treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU4270196A (en) *	1994-10-07	1996-05-02	Lutz Gissmann	Papilloma virus-like particles, fusion proteins and process for producing the same
FR2768749A1 (fr) *	1997-09-22	1999-03-26	Inst Nat Sante Rech Med	Virus artificiels derives de papillomavirus, et leurs utilisations, notamment en therapie genique
DE19812941A1 (de) *	1998-03-24	1999-10-07	Medigene Ag	Arzneimittel zur Vermeidung oder Behandlung von Papillomavirusspezifischem Tumor

1999
- 1999-09-30 SE SE9903534A patent/SE514982C2/sv not_active IP Right Cessation
2000
- 2000-09-19 KR KR1020027004124A patent/KR20020047195A/ko not_active Withdrawn
- 2000-09-19 DE DE60025016T patent/DE60025016D1/de not_active Expired - Lifetime
- 2000-09-19 CN CN00812618A patent/CN1373771A/zh active Pending
- 2000-09-19 EE EEP200200157A patent/EE200200157A/xx unknown
- 2000-09-19 AU AU76951/00A patent/AU771481B2/en not_active Ceased
- 2000-09-19 BR BR0014666-8A patent/BR0014666A/pt not_active IP Right Cessation
- 2000-09-19 IL IL14874100A patent/IL148741A0/xx unknown
- 2000-09-19 HU HU0202770A patent/HUP0202770A3/hu unknown
- 2000-09-19 NZ NZ516725A patent/NZ516725A/xx unknown
- 2000-09-19 CZ CZ20021023A patent/CZ20021023A3/cs unknown
- 2000-09-19 WO PCT/SE2000/001808 patent/WO2001023422A1/en not_active Ceased
- 2000-09-19 JP JP2001526572A patent/JP2003510064A/ja active Pending
- 2000-09-19 MX MXPA02003328A patent/MXPA02003328A/es unknown
- 2000-09-19 EP EP00966633A patent/EP1222200B1/en not_active Expired - Lifetime
- 2000-09-19 HR HR20020092A patent/HRP20020092A2/hr not_active Application Discontinuation
- 2000-09-19 YU YU22202A patent/YU22202A/sh unknown
- 2000-09-19 TR TR2002/00802T patent/TR200200802T2/xx unknown
- 2000-09-19 CA CA002384723A patent/CA2384723A1/en not_active Abandoned
- 2000-09-19 SK SK422-2002A patent/SK4222002A3/sk unknown
- 2000-09-19 RU RU2002111554/13A patent/RU2002111554A/ru unknown
- 2000-09-19 AT AT00966633T patent/ATE313559T1/de not_active IP Right Cessation
- 2000-09-19 PL PL00355012A patent/PL355012A1/pl not_active Application Discontinuation
2002
- 2002-01-31 ZA ZA200200886A patent/ZA200200886B/en unknown
- 2002-02-08 NO NO20020615A patent/NO20020615L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
ATE313559T1 (de)	2006-01-15
NZ516725A (en)	2003-03-28
NO20020615L (no)	2002-05-29
TR200200802T2 (tr)	2002-09-23
SE9903534D0 (sv)	1999-09-30
YU22202A (sh)	2005-06-10
CA2384723A1 (en)	2001-04-05
KR20020047195A (ko)	2002-06-21
DE60025016D1 (de)	2006-01-26
JP2003510064A (ja)	2003-03-18
EE200200157A (et)	2003-04-15
ZA200200886B (en)	2003-03-26
HUP0202770A2 (hu)	2002-12-28
HUP0202770A3 (en)	2004-07-28
CZ20021023A3 (cs)	2002-07-17
WO2001023422A1 (en)	2001-04-05
RU2002111554A (ru)	2004-03-27
MXPA02003328A (es)	2004-09-10
CN1373771A (zh)	2002-10-09
HRP20020092A2 (en)	2003-06-30
EP1222200B1 (en)	2005-12-21
IL148741A0 (en)	2002-09-12
AU771481B2 (en)	2004-03-25
PL355012A1 (pl)	2004-03-22
BR0014666A (pt)	2002-06-18
EP1222200A1 (en)	2002-07-17
NO20020615D0 (no)	2002-02-08
SK4222002A3 (en)	2002-10-08
SE9903534L (sv)	2001-03-31
AU7695100A (en)	2001-04-30

Legal Events

Date	Code	Title	Description
2007-06-19	NUG	Patent has lapsed

Publication	Publication Date	Title
Gambhira et al.	2007	Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2
Jochmus et al.	1999	Chimeric virus-like particles of the human papillomavirus type 16 (HPV 16) as a prophylactic and therapeutic vaccine
Embers et al.	2002	Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein
Schiller	1999	Papillomavirus-like particle vaccines for cervical cancer
Christensen et al.	1996	Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus
Schellenbacher et al.	2009	Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines
Karanam et al.	2009	Developing vaccines against minor capsid antigen L2 to prevent papillomavirus infection
Palmer et al.	2006	Protection of rabbits against cutaneous papillomavirus infection using recombinant tobacco mosaic virus containing L2 capsid epitopes
Rose et al.	1998	Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies
Campo et al.	2010	Papillomavirus prophylactic vaccines: established successes, new approaches
Shi et al.	2001	Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses
US5874089A (en)	1999-02-23	Protecting against canine oral papillomavirus (copy)
Fligge et al.	2001	Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33
Palmer et al.	2009	Recombinant vaccines for the prevention of human papillomavirus infection and cervical cancer
EP1222200B1 (en)	2005-12-21	Fusion protein between HPV-L1 and a peptide, capable of forming a VLP and that functions as a vehicle for introduction of a peptide in a cell and medical uses thereof
Liu et al.	2002	Route of administration of chimeric BPV1 VLP determines the character of the induced immune responses
EP0957936B1 (en)	2006-10-04	Formulations of recombinant papillomavirus vaccines
US20040146531A1 (en)	2004-07-29	Virus-like particles devoid of HPV 16 type-specific antibody epitopes as carriers of peptides for introduction into cells
Ellis	1996	The new generation of recombinant viral subunit vaccines
CN109381699A (zh)	2019-02-26	一种广谱hpv疫苗及其制备方法
Sapp et al.	1996	Synthesis, properties and applications of papillomavirus-like particles
Deng et al.	2011	The preparation of human papillomavirus type 58 vaccine and exploring its biological activity and immunogenicity in vitro
WO2008115631A9 (en)	2008-11-20	Plant-produced compositions for treating papillomavirus infection and related methods
EP0824359A1 (en)	1998-02-25	Peptide-based vaccine against papillomavirus infection
Im et al.	2001	Prevention of cervical cancer with vaccines